The WACC of Innovation Pharmaceuticals Inc (IPIX) is 6.0%.
Range | Selected | |
Cost of equity | 26.2% - 44.1% | 35.15% |
Tax rate | 26.2% - 27.0% | 26.6% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 5.3% - 6.6% | 6.0% |
Category | Low | High |
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 4.6% | 5.6% |
Adjusted beta | 4.85 | 7.01 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 26.2% | 44.1% |
Tax rate | 26.2% | 27.0% |
Debt/Equity ratio | 12.57 | 12.57 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 5.3% | 6.6% |
Selected WACC | 6.0% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
IPIX | Innovation Pharmaceuticals Inc | 12.57 | -4.75 | -0.47 |
AIM | AIM ImmunoTech Inc | 0.34 | 0.85 | 0.68 |
APM | Aptorum Group Ltd | 0.49 | 1.63 | 1.2 |
ARMP | Armata Pharmaceuticals Inc | 1.17 | 0.14 | 0.08 |
AZRX | AzurRx BioPharma Inc | 0.02 | 1.58 | 1.56 |
BIOC | Biocept Inc | 2.11 | 1.23 | 0.48 |
EDT.TO | Spectral Medical Inc | 0.06 | 0.59 | 0.56 |
GALT | Galectin Therapeutics Inc | 0.67 | 1.24 | 0.83 |
LMNL | Liminal BioSciences Inc | 0.04 | 0.66 | 0.64 |
OGEN | Oragenics Inc | 0.3 | 1.96 | 1.6 |
SBM.V | Sirona Biochem Corp | 0.14 | 1.61 | 1.46 |
Low | High | |
Unlevered beta | 0.64 | 0.83 |
Relevered beta | 6.75 | 9.97 |
Adjusted relevered beta | 4.85 | 7.01 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for IPIX:
cost_of_equity (35.15%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (4.85) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.